The scientific community continues to make progress at uncovering the elements that could lead to a cure for HIV. The virus ...

After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...

Shigella flexneri is the leading cause of endemic diarrhea and dysentery in some countries with low-to-middle incomes. There is still a lack of a licensed vaccine against this pathogen.

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in ...

Epitel Inc. raised $26 million in a series B financing round that will be used to expand market access for its wireless ...

Veraxa Biotech AG has reported the advancement of its bispecific antibody-drug conjugate (bsADC) program VXA-222, following achievement of a technical milestone in its alliance with Omniab Inc. The ...

Bad news from the Novo Nordisk A/S phase III trial called Zeus with IL-6 inhibitor ziltivekimab struck a blow to some drug developers’ theory about heart disease – and to their stocks. An update on ...

News of the first-ever successful head-to-head phase III study testing an oral antiviral therapy for hepatitis C virus (HCV) ...

Scientists in the U.K. have used genome mining to identify bacterial species capable of producing novel polyene antifungal compounds that are both more effective and have a more benign side effect ...

Tidalsense Ltd. raised $19 million in a funding round for N-Tidal Diagnose, its AI-based diagnostic platform, which can identify chronic obstructive pulmonary disease (COPD) in as little as five ...

Boston Scientific Corp. cut its guidance for the year on the back of increasing pressure on its Watchman and ...

Core Biomedicine Inc. has completed a $21 million series A financing and been awarded a Japan Agency for Medical Research and Development (AMED) grant to advance its lead programs through discovery ...